Cannabidiol decreases histological intestinal injury in a neonatal experimental model of necrotizing enterocolitis
10.1186/s42826-024-00211-9
- Author:
Nerea Huertos SOTO
1
;
Juan Manuel Gómez CERVANTES
;
María Jesús Fernández ACEÑERO
;
María del Carmen Soto BEAUREGARD
Author Information
1. Physiopathology and neurological therapy of INA (NEURO-INA-IN). Health Research Institute of the Hospital Clínico San Carlos (IdISSC). Community of Madrid’s Youth Employment Program (PEJ-2021 AI/BMD 21347), Madrid, Spain
- Publication Type:RESEARCH
- From:Laboratory Animal Research
2024;40(2):258-268
- CountryRepublic of Korea
- Language:EN
-
Abstract:
Background:Necrotizing enterocolitis (NEC) is a severe inflammatory bowel disease in neonates. Our group has developed an experimental model of NEC, with an effectiveness of 73%. Cannabidiol (CBD) is an innovative treatment for neonatal cerebral hypoxic-ischemic pathologies due to its neuroprotective effect, as a potent anti-inflammatory and reducing oxidative stress substance. Our aim was to evaluate the effect of CBD on intestinal lesions in an experimental model of NEC.
Results:Mortality and intestinal histological damage was significantly lower in the CBD group compared to the rest (p<0.05), establishing CBD as a protective factor against the development of NEC (OR=0.0255; 95% CI=0.0015-0.4460).At IHQ level (TUNEL technique), a lower cell death rate was also observed in the CBD group compared to the VEH group (p<0.05).
Conclusions:In our experimental model, intraperitoneal CBD acts as a protective factor against NEC, resulting in less histological damage and a lower rate of intestinal cell death.
